UNIVERSI
TÄ
TS-
BIBLIOTHEK
P
ADERBORN
Anmelden
Menü
Menü
Start
Hilfe
Blog
Weitere Dienste
Neuerwerbungslisten
Fachsystematik Bücher
Erwerbungsvorschlag
Bestellung aus dem Magazin
Fernleihe
Einstellungen
Sprache
Deutsch
Deutsch
Englisch
Farbschema
Hell
Dunkel
Automatisch
Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist
gegebenenfalls
nur via VPN oder Shibboleth (DFN-AAI) möglich.
mehr Informationen...
Universitätsbibliothek
Katalog
Suche
Details
Zur Ergebnisliste
Ergebnis 11 von 20
Datensatz exportieren als...
BibTeX
Molecular adsorbent recirculating system in patients with early allograft dysfunction after liver transplantation: A pilot study
Liver transplantation, 2006-09, Vol.12 (9), p.1357-1364
Hetz, Hubert
Faybik, Peter
Berlakovich, Gabriela
Baker, Amir
Bacher, Andreas
Burghuber, Christopher
Sandner, Sigrid E.
Steltzer, Heinz
Krenn, Claus Georg
2006
Volltextzugriff (PDF)
Details
Autor(en) / Beteiligte
Hetz, Hubert
Faybik, Peter
Berlakovich, Gabriela
Baker, Amir
Bacher, Andreas
Burghuber, Christopher
Sandner, Sigrid E.
Steltzer, Heinz
Krenn, Claus Georg
Titel
Molecular adsorbent recirculating system in patients with early allograft dysfunction after liver transplantation: A pilot study
Ist Teil von
Liver transplantation, 2006-09, Vol.12 (9), p.1357-1364
Ort / Verlag
Hoboken: Wiley Subscription Services, Inc., A Wiley Company
Erscheinungsjahr
2006
Quelle
MEDLINE
Beschreibungen/Notizen
Early allograft dysfunction (EAD) after orthotopic liver transplantation (OLT) causes marked morbidity and mortality. We conducted a prospective pilot study to assess the safety and efficacy of molecular adsorbent recirculating system (MARS) in treatment of EAD after OLT. Twelve consecutive adult liver allograft recipients with a median age of 48 years, 9 of whom were male, were prospectively included and supported with MARS. EAD was defined as the presence of at least 2 of the following: serum bilirubin >10 mg/dL, prothrombin time <40%, aspartate aminotransferase or alanine transferase >1,000 U/L, and plasma disappearance rate of indocyanine green (PDRICG) <10% per minute within 72 hours after reperfusion. One‐year patient and graft survival was 66%. There was a significant decrease in serum bilirubin (P = 0.002), serum creatinine (P = 0.006), and aspartate aminotransferase (P = 0.005) and a significant increase in PDRICG (P = 0.007) after MARS treatment. Prothrombin time, albumin level, and platelet count remained stable. Sustained improvement of renal and neurological function and of mean arterial pressure were observed. No MARS‐related adverse effects occurred. MARS treatment provides a safe approach to the treatment of EAD after OLT. On the basis of this pilot study, a multicenter randomized clinical trial that uses MARS treatment in EAD after OLT has been initiated. Liver Transpl 12:1357‐1364, 2006. © 2006 AASLD.
Sprache
Englisch
Identifikatoren
ISSN: 1527-6465
eISSN: 1527-6473
DOI: 10.1002/lt.20804
Titel-ID: cdi_proquest_miscellaneous_68808715
Format
–
Schlagworte
Adsorption
,
Adult
,
Animals
,
Delayed Graft Function - therapy
,
Female
,
Humans
,
Immunoglobulins - therapeutic use
,
Indocyanine Green
,
Liver Transplantation
,
Male
,
Middle Aged
,
Rabbits
,
Thymus Gland - immunology
,
Transplantation, Homologous
,
Transplants
Weiterführende Literatur
Empfehlungen zum selben Thema automatisch vorgeschlagen von
bX